BPC-157 Tendon Repair: What Rat and Human Studies Show

Does BPC-157 Help With Tendon Repair?

BPC-157 tendon repair has good results in rats but almost no human proof. In rodent (rat) studies, it helped a cut knee ligament heal. It also helped an Achilles tendon cut from the bone, and a cut muscle-tendon join. None of the human studies the FDA lists tested a tendon injury.

It is a peptide, a short chain of amino acids, the building blocks of protein. It has 15 of them and comes from a protein in human stomach juice (Chang et al.). A recent review found 36 studies of it in sports medicine. Only one of them was in people (Vasireddi et al.).

BPC-157 Mechanism of Action: Tendon Repair in Lab Studies

The studies below used lab dishes, chick eggs, rat tissue and, in one case, living rats. None of them tested the peptide in a person.

The first set looked at blood supply. In one study, the peptide raised the number of blood vessels in a chick egg membrane and in a lab dish. Rats with a blocked blood supply to a hind leg got their blood flow back faster. In human blood vessel cells, it raised VEGFR2. That is a receptor, a docking point on a cell, for a growth signal called VEGF. It did not raise VEGF-A itself (Hsieh et al., 2017).

A later study used the aorta, the body's main artery, taken out of rats. The peptide made it wider, and more so at higher strengths. It worked through nitric oxide, a gas that relaxes blood vessels. In human vessel-lining cells, it switched on eNOS, the enzyme that makes nitric oxide. The signal ran through a chain called Src-Caveolin-1 (Hsieh et al., 2020).

The second set looked at tendon cells. Researchers grew small pieces of rat Achilles tendon in a dish. With the peptide, fibroblasts grew out of the pieces faster. Fibroblasts are the cells that build tendon. It also made these cells move faster, and the effect rose with the dose. It helped them survive a chemical stress test. But it did not directly make them multiply. The authors link this to the FAK-paxillin pathway, a signal route cells use to move (Chang et al.).

The same group then tested rat tendon cells again. The peptide raised their number of growth hormone receptors. The rise grew with both the dose and the time. When growth hormone was added, the treated cells multiplied faster (Chang et al., 2014).

What Rat Studies Show on BPC-157 Tendon Repair

Five rodent (rat) injury studies on this page tested BPC-157 tendon repair directly. Four came from research groups in Zagreb, Croatia.

The first is a knee ligament study. Researchers cut the medial collateral ligament, the band on the inner side of the knee. The peptide went into the belly at 10 micrograms or 10 nanograms per kilogram, once daily. Other rats got it as a cream on the wound or in their drinking water. All three routes worked. The treated rats showed steady gains in function, strength and tissue repair. The gains were tracked for 90 days after surgery (Cerovecki et al.).

The second is an Achilles tendon-to-bone study. Researchers cut the Achilles tendon away from the heel bone. The authors say this injury does not heal on its own. The peptide went into the belly once daily. Treated rats walked better. Their tendons took more force before they broke, called load to failure. Stiffness and a measure of elasticity also rose. Collagen fibres, the tendon's main building blocks, were better lined up. Methylprednisolone, a corticosteroid drug, made healing worse. The peptide given with it cut that harm (Krivic et al.).

The third is a myotendinous junction study. That is where muscle meets tendon. Researchers cut the quadriceps tendon away from the thigh muscle. The authors say this injury cannot heal on its own in rats. The peptide went into the belly or into drinking water. By days 28 and 42, treated rats had no inflammatory infiltrate, a build-up of immune cells. The new tissue was well lined up. The authors also report full return of function and less muscle wasting (Japjec et al.).

The fourth is the earliest. Researchers cut the Achilles tendon across, leaving a large gap between the cut ends. The peptide went into the belly once daily. Untreated tendons healed poorly. Treated tendons took more force before they broke, worked better and showed better tissue repair. In time, the tendon was whole again (Staresinic et al.).

The fifth compared BPC-157 with TB-500. Researchers cut and repaired the Achilles tendon in 32 rodents (rats), eight per group. One group got BPC-157, one TB-500, one both, and one nothing, for four weeks. TB-500 alone made the repaired tendons significantly stronger than no treatment. BPC-157 alone gave better numbers, but its total scores did not reach significance. The pair did no better than either peptide alone. The authors call it an exploratory study (Biçer et al.).

How Strong Is the Human Evidence for BPC-157 Tendon Repair?

Human evidence for BPC-157 tendon repair is very thin. A 2025 systematic review found 544 articles. After repeats were taken out, it kept 36 studies. Of those, 35 were preclinical, meaning done in animals or cells. Only one was clinical, meaning done in people (Vasireddi et al.).

That one study appears to be a knee pain report from a clinic in Florida (Lee and Padgett). It looked back at the records of 17 patients. Each had the peptide put into the knee joint for knee pain of many kinds. Staff reached 16 of them by phone. Of the 12 who had it alone, 11 reported significant improvement in knee pain. No tool was used to measure function. There was no group to compare with. The summary does not split the results by cause of pain.

The 2025 review sums up the same report in a different way. It says 7 of 12 patients reported relief for more than 6 months (Vasireddi et al.).

The FDA's BPC-157 briefing document from 2026 lists five human studies in all. Two compared it with a placebo, a dummy treatment. Both gave it as an enema, a liquid put into the rectum. Both were reported only as meeting abstracts, short summaries given at a conference. The other three are the knee report, a bladder study and a study of two people. None of the five tested a tendon injury.

A 2026 sports medicine review looked at six peptides, this one among them. Across the six peptides, it found modest gains at best in human data for metabolic bone health. The same was true for knee pain from wear and tear (Tewari et al.). The summary does not say which peptides these gains came from.

Is There a BPC-157 Dosage for Tendon Repair?

No study has tested a BPC-157 dosage for tendon repair in people. The table lists the doses used in the studies on this page. Each is given in its source's own terms. The rat doses are per kilogram (kg) of body weight. A microgram is a thousandth of a milligram (mg). A nanogram is a thousandth of a microgram.

None of these doses was tested on a tendon in people. The knee report holds the only human joint dose in these sources. In the rat ligament and muscle-tendon studies, the peptide also worked in drinking water. Our BPC-157 dosing protocol page lists the human doses we found, each with its source.

How Long Did BPC-157 Tendon Repair Take in Rats?

No study has timed BPC-157 tendon repair in people. The rat timings depend on how each study was set up.

The Achilles study checked rats at days 1, 4, 7, 10, 14 and 21. It reports better healing with the peptide across that span (Krivic et al.). The muscle-tendon study checked rats at days 7, 14, 28 and 42. The well lined-up new tissue was seen at days 28 and 42 (Japjec et al.). The knee ligament study tracked healing for 90 days (Cerovecki et al.). These timings come from rats, not people.

Does BPC-157 Tendon Repair Research Cover Cartilage or the Labrum?

No. The BPC-157 tendon repair studies above tested ligament, tendon and muscle, not cartilage. Cartilage is the smooth, tough tissue that lines joints. The labrum is a rim of it around the shoulder and hip sockets. A PubMed search we ran on 5 October 2026 found no animal or human study that tested the peptide on cartilage or the labrum.

The knee report's authors wrote that the peptide could one day repair tears and build cartilage. Their study did not measure either. It asked patients about their pain by phone, with no scans (Lee and Padgett).

The 2026 sports medicine review went further. It said peptide supplements should not now be advised as a stand-in for standard bone and joint care. It said the same about adding them on top of that care (Tewari et al.).

BPC-157 vs TB-500 for Tendon Repair: What Has Been Studied?

One rodent (rat) study has compared BPC-157 vs TB-500 for tendon repair, the fifth Achilles study above (Biçer et al.). TB-500 alone made the repaired tendons significantly stronger. BPC-157 alone did not reach significance, and the pair added nothing. No study has compared the two in people. The FDA's TB-500 briefing document found no clinical studies or human exposure data for TB-500 by any route.

TB-500 is a lab-made chain of seven amino acids. It copies amino acids 17 to 23 of thymosin beta-4, a natural protein that is 43 amino acids long. It also has a small chemical cap. The FDA says thymosin beta-4 and TB-500 are not the same substance. In its May 2026 briefing document, the FDA said its review weighed against allowing TB-500 in compounding, when a pharmacy makes a drug to order. It said it would not make a final decision until after its advisory committee had met. Our TB-500 dosage page covers what the FDA found.

The only human data on the two peptides together is in the knee report. Four of its 16 patients had shots of both BPC-157 and thymosin beta-4. The authors say 75% of them, 3 of 4, had significant improvement in knee pain (Lee and Padgett). That was thymosin beta-4, not TB-500. Our full comparison of the two breaks down what each one's evidence actually covers.

Is BPC-157 Tendon Repair Safe?

No study has measured the safety of BPC-157 tendon repair in people. The 2025 review found no clinical safety data. In animal safety studies, it found no harmful effects across several organ systems (Vasireddi et al.).

One of those animal studies tested mice, rats, rabbits and dogs. The peptide was well tolerated, with no serious toxicity. In dogs, creatinine fell at 2 mg per kg but not at lower doses. Creatinine is a blood marker of kidney function. The dogs recovered on their own after 2 weeks off the peptide (Xu et al.).

In people, a 2025 pilot study gave the peptide by drip into a vein to 2 healthy adults. Both had had it by drip before. They got 10 mg on day 1 and 20 mg on day 2. No side effects were reported (Lee and Burgess).

The FDA looked at all five human studies. It found "insufficient clinical safety information to characterize the safety profile" of the peptide. The FDA says these studies were short and small. The two enema studies gave the peptide for two weeks at most. A Phase I trial, a first safety trial in people, was set up for 42 healthy volunteers in 2015. Its status is unknown, and it has never posted results (trial record).

USADA, the US anti-doping agency, says the FDA has not approved it. Nor has any other global health authority. The 2025 review adds that harm is possible from poorly controlled manufacturing or contamination. We keep a vendor-neutral list on our recommended sources page.

Bibliography

• Chang et al. 2011, The promoting effect of pentadecapeptide BPC 157 on tendon healing
• Cerovecki et al. 2010, Pentadecapeptide BPC 157 improves ligament healing in the rat
• Krivic et al. 2006, Achilles detachment in rat and stable gastric pentadecapeptide BPC 157
• Japjec et al. 2021, BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
• Staresinic et al. 2003, Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon
• Biçer et al. 2026, Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
• Chang et al. 2014, BPC 157 enhances growth hormone receptor expression in tendon fibroblasts
• Hsieh et al. 2017, Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
• Hsieh et al. 2020, Modulatory effects of BPC 157 on vasomotor tone and eNOS pathway
• Vasireddi et al. 2025, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
• Lee and Padgett 2021, Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
• Lee and Burgess 2025, Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
• Xu et al. 2020, Preclinical safety evaluation of body protective compound-157
• Tewari et al. 2026, Peptide Supplements and Their Therapeutic Applications in Sports Medicine
• US Food and Drug Administration 2026, BPC-157 briefing document, Pharmacy Compounding Advisory Committee
• US Food and Drug Administration 2026, TB-500 briefing document, Pharmacy Compounding Advisory Committee
• ClinicalTrials.gov, NCT02637284: PCO-02 Safety and Pharmacokinetics Trial

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.